Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

roughout the duration of the 12-month study, or in the subsequent two years since the study formally ended.

About Neurologix

Neurologix, Inc. is a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and other neurodegenerative and metabolic disorders. Neurologix's core technology, "NLX," is currently in the clinical development stages, having recently been tested in a company-sponsored Phase I human clinical trial to treat Parkinson's disease.

Cautionary Statement Regarding Forward-looking Statements

This news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any futu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/25/2009).... 25 /PRNewswire-Asia-FirstCall/ -- China Sky One,...pany") (Nasdaq: CSKI ), a,leading fully integrate...over-the-counter drugs in the People,s Republic of...ecently passed the Chinese National Institute for,...cts ("ICPBP") examination,for two of its new produ...
(Date:11/25/2009)...Newswire/ -- Reportlinker.com announces that a new...gue: ,, Mammography Equipment - A Global Mark...m/p0164330/Mammography-Equipment---A-Global-Market...t cancer in industrialized as well as developing n... the mammography market. Globally, escalating awar...
(Date:11/25/2009)...v. 25 Swissray International, Inc....phy ( ddR ) systems, announced today that its oper...tor with a long term view towards growing Swissray... all assets and intellectual property, as well as ... and growth Swissray is now poised to move to the ...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Swissray International Announces New Ownership 2AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 1AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 1Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 1Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 5Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 7Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 8Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 9Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 10
(Date:11/27/2009)...7 Shamir Optical Industr...ovider of innovative products and technology to th... board of directors had declared a dividend distri...pproximately NIS 37.62 million based on the Novemb...pproximately US$ 0.609 (approximately NIS 2.3 base...
(Date:11/27/2009)...rade; announced today that Spectrum Health (Grand ...prise orthopedic templating solution and its Traum... (PRWEB) November 27, 2009 -- Voyant Health...d Rapids, Michigan) has licensed its TraumaCad Ent...umaCad Extend workflow solution, to allow its orth...
(Date:11/26/2009)...RNewswire/ -- The diabetes population in the Unite... and annual medical spending on the disease is pro...oday, according to a study published in the Decemb...ng Diabetes ® Program (NCDP), a program of No...om the University of Chicago. ,, According to t...
(Date:11/26/2009)... from the North Pole, Textsanta.net lets parents s..., North Pole, AK (PRWEB) -...s at the North Pole Santa Claus has added SMS text...e informed of his Christmas progress at the North ...nt have identified a large and growing percentage ...
(Date:11/25/2009)...wire-USNewswire/ -- When most people hear the acro...practor can also give patients the help they need....ch is where your jaw (mandible) contacts/connects ...ommon symptoms associated with TMJ dysfunction are.... But many other symptoms can be caused from TMJ ...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...inois have found that a molecular pathway known to...humans is also critical to the pathology// of skel...d to advances in the palliative care of companion ...e of an enzyme, receptor activator of nuclear fact...
... not linked to a cluster of cases in Clendon, Sout...been treated for typhoid in Porirua and those case...edical officer of health, regional public health, ... the cases were in late January and one was early ...
...ies is expected to aid in longevity of life. This ...e Zutphen Study.// According to this study, a ...ular deaths and increase the life span in middle a...n body. This research studied the pattern of a...
... of losing weight. Belgium’s Janssen Animal Health...gs shed the flab.// The drug works by blocking...eat into their bloodstream. It does not affect t...y to beg for its favorite snack. Studies acros...
...nted by Finance minister P.Chidambaram has drawn c...his introductory remarks he// said: 'The education...funds. In 2007-08, I propose to enhance the alloca...ng has been a high priority and smokers have alway...
...ssue of the journal SLEEP finds that people with o... for cardiovascular disease.// The study att...ascular disease to heightened recognition and a ri... "There is abundant physiologic evidence imp...
Other Medicine News:Health News:Insights into Osteosarcoma in Cats and Dogs may Improve Palliative Care 2Health News:Union Budget: Impact on Health Sector 2Health News:Union Budget: Impact on Health Sector 3Health News:Sleep Well, Have a Healthy Heart ! 2
The Closer
5.2F Supertorque Plus
Torcon NB Advantage
8F Standard
Medicine Products: